Search Medical Centers

CAR-T-cell-Treatment Abroad

A list of leading international hospitals offering CAR-T-cell-Treatment to international patients.

Sourasky Medical Center

The Oncology Institute serves a broad population of cancer patients from central Israel and throughout the country. The fast-track appointment service enables patients to be seen for their initial visit within 48 hours of contacting the institute.

4 listed oncologists:

view all >

Prof. Ido Wolf

Head of Medical Oncology Division

Prof. Yehuda Kolander

Orthopedic Oncology Acting Director


Procedure Prices


120,000 - 135,000 US$

Sheba Medical Center

The largest medical center in Israel and the Middle East, internationally renowned for it's medical excellence. Around 31,000 inpatients are treated annually.

18 listed oncologists:

view all >

Prof. Eitan Friedman

Director and founder of the Suzanne Levy-Gertner Oncogenetics Unit

Prof. Zvi Symon

Director, Radiation Oncology Department


Procedure Prices


upon request

Cancer treatment centers (Page 1 of 1)

About CAR-T-cell-Treatment

This information is intended for general information only and should not be considered as medical advice on the part of Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

CAR-T-Cell Treatment Abroad: A New Hope for Cancer Patients

CAR-T cell therapy has shown promising results in treating various types of cancer, including leukemia and lymphoma. However, it is a highly specialized and complex treatment that requires specialized facilities and highly trained medical professionals. For this reason, many patients choose to travel abroad to receive CAR-T cell therapy.

Several countries around the world offer CAR-T cell therapy, including the United States, Europe, China, and Australia. In the United States, the Food and Drug Administration (FDA) has approved two CAR-T cell therapies for the treatment of certain types of leukemia and lymphoma.

What is CAR-T-cell Treatment?

CAR-T-cell (chimeric antigen receptor T-cell) therapy is a type of cancer treatment that harnesses the power of the immune system to fight cancer. In this treatment, immune cells are extracted from a patient's body and genetically modified in a lab to recognize and attack cancer cells. The modified cells are then infused back into the patient's bloodstream, where they seek out and destroy cancer cells.

Sub-procedures/types of Treatment

There are currently two FDA-approved CAR-T-cell therapies: Kymriah and Yescarta. Both are used to treat certain types of blood cancer, including leukemia and lymphoma. However,CAR-T-cell therapy is a relatively new and rapidly evolving field, and clinical trials are ongoing to explore its potential for treating other types of cancer.

Other Points of Interest

CAR-T-cell therapy is a complex and specialized treatment that is not widely available. Patients seeking this treatment may need to travel abroad to find a facility that offersit. Additionally, the cost of CAR-T-cell therapy can be prohibitively high,with prices ranging from $373,000 to $475,000 per treatment in the US.

In Europe, CAR-T cell therapy is also available, with several countries offering this treatment, including Germany, France, and the United Kingdom. The cost of CAR-T cell therapy in Europe can vary depending on the country and the specific treatment being offered. In general, the cost is lower than in the US, with estimates ranging from €300,000 to €400,000.

China has also emerged as a major player in the field of CAR-T cell therapy, with several hospitals and medical centers offering this treatment. The cost of CAR-T cell therapy in China is generally lower than in the US and Europe, with estimates ranging from $70,000 to $150,000.

Australia has also recently approved CAR-T cell therapy for the treatment of certain types of leukemia and lymphoma. However, as with the other countries, the cost of CAR-T cell therapy in Australia can be high, with estimates ranging from AUD$500,000 to AUD$750,000.

Duration of procedure/surgery : The infusion of genetically modified T-cells typically takes several hours and is performed as an outpatient procedure. However, patients may need to remain in the hospital for monitoring and supporti

Number of sessions required : Typically, CAR-T-cell therapy is administered as a one-time treatment. However, patients may require additional treatments if their cancer returns or does not respond to the initial therapy.

Days admitted : Patients typically do not need to be admitted to the hospital for CAR-T-cell therapy but may require hospitalization for monitoring and supportive care.

Anesthesia : Anesthesia is not required for CAR-T-cell therapy.

Recovery : Recovery from CAR-T-cell therapy varies from patient to patient. Some patients may experience significant improvement in their cancer symptoms shortly after treatment, while others may take longer to see results. Patients may experience side effects from the treatment, such as fatigue, nausea, and infections. Follow-up care is essential to monitor for signs of cancer recurrence and manage any ongoing side effects.

Risks : CAR-T-cell therapy carries the risk of several serious complications, including cytokine release syndrome (CRS) and neurotoxicity. CRS is a severe immune reaction that can cause fever, low blood pressure, and organ damage. Neurotoxicity can cause confusion, seizures, and other neurological symptoms. These risks are carefully managed by medical professionals who closely monitor patients for signs of complications and provide supportive care as needed.

After care : Patients who undergo CAR-T-cell therapy will require ongoing monitoring and care to manage any side effects and monitor for cancer recurrence. It is important for patients to work closely with their medical team to develop a comprehensive aftercare plan.

Learn more about CAR-T-cell-Treatment

Browse by country

Copyright © 2008 - 2024, All Rights Reserved